EAST BRUNSWICK, New Jersey-- Savient Pharmaceuticals Inc. (SVNT) announced the appointment of Clifford T. Bacsik, as vice president and chief accounting officer, effective March 7, 2005.
Bacsik will report to Lawrence A. Gyenes, senior vice president, chief financial officer and treasurer. In this position, Bacsik will be responsible for Savient's internal and external financial reporting, including compliance with U.S. generally accepted accounting principles and the accounting rules and regulations of the U.S. Securities and Exchange Commission.
Bacsik was most recently an independent consultant providing guidance on the implementation of the Sarbanes-Oxley Act. Prior to his consulting role, he was the director, accounting for Agere Systems where he was responsible for the consolidation of the company's global financial results, preparation of various SEC filings and the implementation of Sarbanes-Oxley documentation, testing and reporting. He also held positions with Novartis, Unilver-Bestfoods and Touche Ross. Bacsik received his MBA, finance degree from Fairleigh Dickinson University and his BBA in accounting from the University of Notre Dame. He is a CPA in New Jersey.
Savient Pharmaceuticals, Inc. markets Oxandrin (oxandrolone, USP) and Delatestryl (testosterone enanthate) in the United States. The company's subsidiary, Rosemont Pharmaceuticals Limited, develops, manufactures, and markets products for the U.K. pharmaceutical market. The company's Israeli subsidiary, Bio-Technology General (Israel) Ltd., manufactures and markets in Israel Bio-Tropin (recombinant human growth hormone), BioLon (sodium hyaluronate for ophthalmic surgery), Bio-Hep-B (hepatitis B vaccine), and Arthrease (sodium hyaluronate for osteoarthritis).